Compare Abeona Therapeutics Inc (ABEO) vs Workday Inc (WDAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Workday Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Workday Inc trades at $138.24 (market cap $35.48B). The key difference: Workday Inc is far larger — about 95× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Workday Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | WDAY | |
|---|---|---|
Market Cap | $373.32M | $35.48B |
Sector | Health | Technology |
52-Week High | $7.23 | $247.69 |
52-Week Low | $4.17 | $112.55 |
Enterprise Value | $228.22M | $34.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Workday (WDAY) trades at $143.65, up 6.09% with strong technical momentum above key resistance at $141. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $2.66 vs. $2.51 expected) and 14.3% y/y subscription revenue growth. Recent AI product launches, including agentic AI tools with 200%+ ACV growth, position the company for continued expansion despite a recent lawsuit over AI bias in HR tools.
Outlook remains positive with 55.5% analyst buy ratings and $157.30 consensus target (9.5% upside). Key risks include the California AI bias lawsuit, competitive pressure in enterprise software, and valuation concerns at 42.99 P/E. Strong cash flow generation ($2.46B operating cash flow) supports growth investments while net cash flow turned negative due to strategic financing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
